3-nitropropionic acid has been researched along with Parkinson Disease in 5 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the pathogenesis of Parkinson's disease and Huntington's disease excitotoxicity may play an important role." | 1.33 | Effects of mitochondrial toxins on the brain amino acid concentrations. ( Hartai, Z; Juhasz, G; Kekesi, KA; Klivenyi, P; Vecsei, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, L | 1 |
| Calingasan, NY | 1 |
| Wille, EJ | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Ferrante, RJ | 1 |
| Beal, MF | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Klivenyi, P | 1 |
| Kekesi, KA | 1 |
| Hartai, Z | 1 |
| Juhasz, G | 1 |
| Vecsei, L | 1 |
| Brouillet, E | 1 |
| Hantraye, P | 1 |
| Han, J | 1 |
| Cheng, FC | 1 |
| Yang, Z | 1 |
| Dryhurst, G | 1 |
1 review available for 3-nitropropionic acid and Parkinson Disease
| Article | Year |
|---|---|
Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Disease Models, Anim | 1995 |
4 other studies available for 3-nitropropionic acid and Parkinson Disease
| Article | Year |
|---|---|
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Effects of mitochondrial toxins on the brain amino acid concentrations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Chemistry; Cerebral Cortex | 2005 |
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 1999 |